Bioasis Technologies

Delivering effective brain therapies for rare and orphan diseases
TSXV: $BTI | OTCQB: $BIOAF

[Bioasis Technologies @BioasisUS]

Bioasis' latest feature in @BNNBloomberg discusses our recent partnerships with Janssen Biotech & Neuramedy Co., as well as the acquisition of EGF platform assets from the founders of Cresence AS, which paved the way for us to become a clinical-stage company.

Read the article👇

[Bioasis Technologies @BioasisUS]

The 2023 BIO International Convention is back to stand up for science! Bioasis (represented by John Proffett of Shadow Lake Group) will be meeting with potential partners 🤝

🗓️ June 5-8, 2023 | Boston Convention & Exhibition Center

Learn more:
https://t.co/hT0d6JZGYD

[Bioasis Technologies @BioasisUS]

Curious about how Bioasis Technologies is breaking through the blood-brain barrier to develop innovative therapies for neurological diseases?

🎥 Check out our video to learn more about the xB3 platform

[Bioasis Technologies @BioasisUS]

At Bioasis Technologies, we believe everyone deserves access to life-changing therapies for challenging neurological diseases.

That's why our team is leveraging our xB3 platform to develop novel therapies that can cross the blood-brain barrier & provide hope to patients in need.

[Bioasis Technologies @BioasisUS]

🗓 May is #BrainTumorAwarenessMonth, and it's an important time to show support for all those affected by brain cancers.

Let's use this month to raise awareness, educate others, and show compassion for those living with brain cancer.

[Bioasis Technologies @BioasisUS]

🗓️ May is #MSAwarenessMonth and Bioasis is committed to improving the lives of those affected by Multiple Sclerosis through innovative treatments like CRES101 for optic neuritis associated with MS.

[Bioasis Technologies @BioasisUS]

With 1.25 billion people worldwide affected by neurological diseases, the need for effective treatments has never been greater 🧠

We're dedicated to delivering innovative solutions that make a difference in the lives of patients.

Find out more:
https://t.co/wgPFNCg4Il

[Bioasis Technologies @BioasisUS]

Studies have highlighted the role of mutations in the GBA gene as a genetic risk factor for Parkinson's disease.

Our proprietary xB3 platform shows potential as a delivery method for therapeutics targeting the GBA gene & its related pathways.

Details:
https://t.co/qI1vJQ9dp4

[Bioasis Technologies @BioasisUS]

Myelin loss in neuroinflammatory diseases causes morbidity & lacks effective treatment

Bioasis' acquired EGF assets stimulate oligodendrocyte & Schwann cell production - essential myelin-producing cells.

Learn more about our groundbreaking research:
https://t.co/7ISkgsLRyw

[Bioasis Technologies @BioasisUS]

Our proprietary xB3 platform enables the delivery of therapeutics into the brain 💊 🧠

It transports molecules across the blood-brain barrier & into the brain, where they can effectively treat neurological disorders.

Learn more:
https://t.co/gGp5tUoe6L

[Bioasis Technologies @BioasisUS]

At Bioasis, we're dedicated to developing innovative therapies to treat rare and difficult-to-treat brain disorders.

Learn more about rare diseases 👉 https://t.co/GgdxnhpKaB

[Bioasis Technologies @BioasisUS]

Bioasis has provided a business update. Read the full press release 👉 https://t.co/9q5YniJFjJ

[Bioasis Technologies @BioasisUS]

Bioasis is exploring strategic alternatives to enhance shareholder value, including partnerships, financing alternatives & remaining a standalone company.

Check out our website to learn about our ongoing efforts to drive value for our shareholders👇
https://t.co/ApqbtGInSA

[Bioasis Technologies @BioasisUS]

Exciting news! Bioasis will be attending Bio-Europe Spring, one of the largest #biotechnology events in Europe.

This event brings together leading minds in the industry to share insights and forge new partnerships.

We can't wait to connect - learn more👇
https://t.co/i14LyVQmdY

[Bioasis Technologies @BioasisUS]

It's Brain Awareness Week 🧠

We're dedicated to advancing brain health & developing therapies to treat neurological disorders. We support this important initiative & encourage everyone to get involved in raising awareness about brain health.

Details:
https://t.co/rvpQ2EM56V

[Bioasis Technologies @BioasisUS]

Today on #InternationalWomensDay, we celebrate the achievements of women in science globally.

At Bioasis, we're proud to recognize the contributions of women in science, who continue to break barriers & pave the way for new discoveries.

#IWD2023

Learn more👇

[Bioasis Technologies @BioasisUS]

We've highlighted 3 indications that will be prioritized for development of CRES101:

✅ Guillain-Barré Syndrome

✅ Optic Neuritis associated with MS

✅ Chronic Inflammatory Demyelinating Polyneuritis

Details:
https://t.co/7ISkgsMpo4

[Bioasis Technologies @BioasisUS]

It's #RareDiseaseDay, a day to raise awareness about the challenges faced by people living with rare diseases.

At Bioasis, we're committed to developing treatments for rare brain diseases that affect millions of people worldwide.

Learn more👇
https://t.co/kj9UYjZkwG

[Bioasis Technologies @BioasisUS]

As we approach #RareDiseaseDay, we're reminded of the need for innovative treatments for these often-neglected conditions.

At Bioasis, we're proud to be working towards that goal by developing cutting-edge therapies for rare brain disorders.

Details👇
https://t.co/0zNyTsbxbe

[Bioasis Technologies @BioasisUS]

Millions of people around the world are affected by neurodegenerative diseases. 🌎

Developing effective treatments for these diseases remains a critical challenge.

Learn how our in-house development programs are designed to address this challenge: https://t.co/mMJRsW4zKS

[Bioasis Technologies @BioasisUS]

Bioasis is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting and is updating shareholders on its current financial condition.

Get the details👇
https://t.co/xisoLkyRuS